Amoun Pharmaceuticals Co.

Product Data

Each 5 ml ampoule contains: 500 mg Tranexamic
Indications And Usage:
Therapeutic indications Local fibrinolysis For short term use in prophylaxis and treatment in patients at high risk of per - and post-operative haemorrhage following:
  • a) prostatectomy
  • b) conisation of the cervix
  • c) surgical procedures and dental extractions in haemophiliacs
  • General fibrinolysis a) haemorrhagic complications in association with thrombolytic therapy. b) Haemorrhage associated with disseminated intravascular coagulation with predominant activation of the fibrinolytic system.
    History of venous or arterial thrombosis • History of convulsions • Intrathecal and intraventricular injection, intracerebral application (risk of cerebral oedema and convulsions)
    Dosage & Administration:
    Posology and method of administration
    Route of administration: by slow intravenous injection. Local fibrinolysis: the recommended standard dose is 5-10ml (500-1000mg) by slow intravenous injection (1 ml/min), three times daily. Following an initial intravenous injection, subsequent treatment may proceed by intravenous infusion. Following addition to a suitable diluent , Kapron® may be administered at a rate of 25-50 mg/kg body wt/day. Children: In children, for current approved indications, the dosage is in the region of 20 mg/kg/day. However, data on efficacy, posology and safety for these indications are limited. Injectable solution: The efficacy, posology and safety of Tranexamic acid in children undergoing cardiac surgery have not been fully established. Currently available data are limited. Elderly patients: No reduction in dosage is necessary unless there is evidence of renal failure. General fibrinolysis 1. In disseminated intravascular coagulation with predominant activation of the fibrinolytic system, usually a single dose of 10ml (1g) is sufficient to control bleeding. 2 Neutralisation of thrombolytic therapy; 10mg/kg body wt by slow intravenous injection.